Phaseline

Companies › BrightGene Bio-Medical Technology

BrightGene Bio-Medical Technology: clinical trials, targets and expected readouts

2 active drug programs in 13 registered trials: 7 Phase 1, 4 Phase 3, 2 Phase 2; Metabolic and endocrine, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BGM0504 Injection multi-dose pen
GLP-1 receptor agonist
–Phase 3Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes (T2DM); Obesity; Overweight or Obese Participants Without Diabetes …Nov 2026
BGM1812–Phase 1Overweight or Obesity; Healhty–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06911203BGM0504 Injection multi-dose penPhase 2ObesityMetabolic and endocrineJan 2026
NCT07239973BGM0504 Injection multi-dose penPhase 1HealthyMetabolic and endocrineMar 2026
NCT07166081BGM0504 Injection multi-dose penPhase 1Non-diabetic Overweight or ObeseMetabolic and endocrineMar 2026
NCT07382908BGM0504 Injection multi-dose penPhase 1Overweight/ObesityMetabolic and endocrineApr 2026
NCT07382908BGM0504 Injection multi-dose penPhase 1Overweight/ObesityMetabolic and endocrineApr 2026
NCT07294235BGM1812Phase 1Overweight or ObesityMetabolic and endocrineJun 2026
NCT07224399BGM1812Phase 1HealhtyMetabolic and endocrineJul 2026
NCT07566572BGM0504 Injection multi-dose penPhase 1Chinese Healthy VolunteersOtherAug 2026
NCT06716216BGM0504 Injection multi-dose penPhase 3Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineNov 2026
NCT06716203BGM0504 Injection multi-dose penPhase 3Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineNov 2026
NCT07658560BGM0504 Injection multi-dose penPhase 2Overweight or Obese Participants Without DiabetesMetabolic and endocrineFeb 2027
NCT07064486BGM0504 Injection multi-dose penPhase 3Type 2 Diabetes (T2DM)Metabolic and endocrineApr 2027
NCT07743983BGM0504 Injection multi-dose penPhase 3Type 2 Diabetes (T2DM)Metabolic and endocrineSep 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Beijing QL Biopharmaceutical Energenesis Biomedical JCR Pharmaceuticals Viking Therapeutics OPKO Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.